Literature DB >> 11253742

The Vienna Stroke Registry--objectives and methodology. The Vienna Stroke Study Group.

.   

Abstract

The Vienna Stroke Registry (VSR) comprises nine neurological departments of Vienna and was established in 1998. This article describes the objectives and methodology of the VSR. The goals of the VSR are as follows: (1) to document the quality (structure, process, outcome) of medical services and to construct a database which can be used for future adjustment of medical services in Vienna (early stroke intervention, concept of stroke units, rehabilitation services); (2) to guide educational programs; (3) to adjust or establish algorithms for clinical decision making and to analyze predictors of outcome; (4) to document changes in diagnostic and therapeutic strategies over time; (5) to formulate hypotheses about the etiology, pathophysiology, clinical course, and outcome of stroke. Since October 1998 all patients with the presumed diagnosis of a transitory ischemic attack (TIA) or stroke who had been admitted to one of the participating centers within 72 hours of the onset of symptoms were included in the VSR. All patients are prospectively documented according to standardized detailed protocols. The collected data refer to demographic parameters; medical, particularly, vascular history; vascular risk factors; laboratory and technical investigations (including cerebrovascular, cardiological, and neuroradiological findings); details of pharmacological and non-pharmacological treatment; factors influencing the time from the onset of symptoms to hospital admission and the start of therapy; clinical and etiological classification according to pre-specified criteria; neurological and functional impairment at specified time points; structured follow-up investigations at 3, 12, and 24 months after the event. Until September 2000, 2300 patients had been included in the VSR. The target number of 3500 patients will be achieved in the second half of 2001. A baseline description of the VSR population will be given separately.

Entities:  

Mesh:

Year:  2001        PMID: 11253742

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  7 in total

1.  [Acute therapy of ischemic stroke].

Authors:  Wilfried Lang; Wolfgang Lalouschek
Journal:  Wien Med Wochenschr       Date:  2003

2.  Clinical predictors of death in young and middle-aged patients with ischemic stroke or transient ischemic attack: long-term results of the Vienna Stroke Registry: clinical predictors of ischemic stroke mortality in patients <60 years.

Authors:  Stefan Greisenegger; Sonja Zehetmayer; Julia Ferrari; Wilfried Lang; Johanna Fizek; Eduard Auff; Wolfgang Lalouschek; Wolfgang Serles
Journal:  J Neurol       Date:  2011-02-01       Impact factor: 4.849

3.  [Challenges in acute stroke].

Authors:  Wilfried Lang
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

4.  Editorial: Stroke units in Austria: structure, performance and results.

Authors:  Michael Brainin; Wilfried Lang
Journal:  Wien Med Wochenschr       Date:  2008

5.  Prior therapy with antiplatelet agents is not associated with outcome in patients with acute ischemic stroke/TIA.

Authors:  S Greisenegger; S Tentschert; M Weber; J Ferrari; W Lang; W Lalouschek
Journal:  J Neurol       Date:  2006-04-20       Impact factor: 4.849

6.  Polymorphisms associated with both noncardioembolic stroke and coronary heart disease: vienna stroke registry.

Authors:  May M Luke; Wolfgang Lalouschek; Charles M Rowland; Joseph J Catanese; Joel I Bolonick; Nam D Bui; Stefan Greisenegger; Georg Endler; James J Devlin; Christine Mannhalter
Journal:  Cerebrovasc Dis       Date:  2009-09-12       Impact factor: 2.762

Review 7.  A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients.

Authors:  Xingyu Wang; Suzanne Cheng; Victoria H Brophy; Henry A Erlich; Christine Mannhalter; Klaus Berger; Wolfgang Lalouschek; Warren S Browner; Yu Shi; E Bernd Ringelstein; Christof Kessler; Jan Luedemann; Klaus Lindpaintner; Lisheng Liu; Paul M Ridker; Robert Y L Zee; Nancy R Cook
Journal:  Stroke       Date:  2009-01-08       Impact factor: 7.914

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.